Try our Advanced Search for more refined results
October 04, 2016
Amgen Inc. v. Apotex Inc.
Case Number:
17-1010
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
November 13, 2017
Fed. Circ. Clears Apotex In Neulasta Biosimilar Patent Row
A Federal Circuit panel upheld a lower court ruling that found Apotex Inc. did not infringe a patent covering Amgen Inc.'s blockbuster drug Neulasta, while clarifying the amount of weight courts should put on statements made in the prelitigation process by companies making biosimilars.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login